Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX )

18.81 +0.09 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,181,518
Open 18.71
Bid (Size) 18.43 (1)
Ask (Size) 19.47 (1)
Prev. Close 18.72
Today's Range 18.50 - 19.09
52wk Range 17.80 - 41.93
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List
Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. 
Via InvestorPlace

Performance

YTD
-47.72%
-47.72%
1 Month
-14.07%
-14.07%
3 Month
-16.10%
-16.10%
6 Month
-38.21%
-38.21%
1 Year
-33.25%
-33.25%

More News

Read More
Expert Ratings for Amylyx Pharma
Via Benzinga
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
A Preview Of Amylyx Pharma's Earnings
Via Benzinga
Why Shares of Amylyx Pharmaceuticals Were Up Monday
Via The Motley Fool
4 Analysts Have This to Say About Amylyx Pharma
Via Benzinga
7 Analysts Have This to Say About Amylyx Pharma
Via Benzinga
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
3 Biotech Stocks to Buy Before Drug Trials End
Via InvestorPlace
Amylyx Stock Has A Good Entry Point, Says Bullish Goldman Sachs
Via Benzinga
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
What 7 Analyst Ratings Have To Say About Amylyx Pharma
Via Benzinga
Analyst Expectations for Amylyx Pharma's Future
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
Via Benzinga
EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's Amyotrophic Lateral Sclerosis Treatment
Via Benzinga
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics?
Via The Motley Fool
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Via Investor's Business Daily
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
Via MarketBeat
2 Supercharged Growth Stocks to Buy Right Now
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.